Shop our Vitamin D Test! Use code VITD10 & get $10 off.

SHOP TEST

Medical Leadership
& Advisory Board

Clinical and Scientific Leadership

Dr. Guandalini
Head of Clinical Advisory Team
Medical Director of the University of Chicago Celiac Disease Center

Dr. Stefano Guandalini is an internationally recognized expert on celiac disease. He is Professor Emeritus, University of Chicago, and the founder of the University of Chicago Celiac Disease Center. Dr. Guandalini’s clinical and research efforts have greatly influenced the way celiac disease is diagnosed and treated today. His work contributed to the revision of 20-year-old guidelines for celiac disease diagnosis.

Learn more about Dr. Guandalini
Dr. Vigerust
Head of Scientific Advisory Team
Professor Vanderbilt University

Dr. Vigerust is the Director of Clinical Affairs and molecular scientist for a diagnostics laboratory focused around precision medicine, genomics and infectious disease. Dr. Vigerust has published extensively in international journals, presented his research at national and international conferences and is an active editor and reviewer for several prominent journals. Dr. Vigerust has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease and cancer. Dr. Vigerust currently maintains an Adjunct Assistant Professor position at Vanderbilt University Medical Center in the Department of Neurological Surgery and a Clinical Assistant Professor position with the University of Maryland, Eastern Shore School of Pharmacy.

Learn more about Dr. Vigerust

Scientific Advisory Team

Dr. Diamandis
Lunenfeld-Tanenbaum Research Institute, Sinai Health System

Dr. Diamandis is using proteomics and mass spectrometry to discover and validate novel biomarkers for diagnosis and monitoring of cancer. He is examining the role of cardiac glycosides and other compounds as novel therapeutics for cancer. He is also investigating novel ways for prenatal diagnosis of Down Syndrome and other fetal abnormalities by using simple tests in maternal blood. Holds the Hold'em for Life Chair in Prostate Cancer Biomarkers. Dr. Diamandis is the Director of the Advanced Center for Detection of Cancer and is working closely with clinicians at the Koffler Center for Urologic Diseases to study prostate cancer and male infertility.

Learn more about Dr. Diamandis
Dr. Spitz
National Cancer Advisory Board

Dr. Sptiz is a professor in the National Cancer Institute (NCI)-designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, has been appointed by President Barack Obama as a member of the National Cancer Advisory Board (NCAB). A renowned expert in molecular epidemiology, Dr. Spitz has a long-standing interest in genetic susceptibility to lung cancer, with an emphasis on variation among individuals in susceptibility to tobacco carcinogenesis.

Learn more about Dr. Spitz
Dr. Bondy
Associate Director at Baylor College of Medicine

Dr. Bondy is associate director for Cancer Prevention and Population Sciences in the NCI-designated Dan L Duncan Cancer Center, and holds the Dan L Duncan Professorship. She received her undergraduate degree from The University of Texas at Austin and both a master's of science in epidemiology - environmental science and Ph.D. in epidemiology from The University of Texas School of Public Health in Houston. Her research focus is in genetic and molecular epidemiology, and she is at the forefront of developing innovative ways to assess the roles of heredity and genetic susceptibility in the etiology of cancer, primarily brain and breast cancer.

Learn more about Dr. Bondy
Dr. Schuppan
Professor and Director, Celiac Disease and Fibrosis Center at UMC Mainz

Dr. Detlef Schuppan (PhD) is the world’s leading researcher on celiac disease, and is credited with discovering the tTG biomarker which is now the gold standard for screening for Celiac Disease. He is currently the founding director of The Institute for Translational Immunology (TIM), and a professor of internal medicine, gastroenterology, and hepatology at the Medical Center of the Johannes Gutenberg University of Mainz in Germany. He directs the outpatient clinic for celiac disease and small intestinal diseases. He is also a professor of medicine and senior visiting scientist at Harvard Medical School.

Learn more about Dr. Schuppan
Dr. Gibson
Professor of Medicine at Harvard Medical School

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher and educator who pioneered our understanding of the "open artery hypothesis" as well our understanding of the importance of restoring flow downstream in the capillary bed in the "open microvasculature hypothesis" in heart attack. Gibson has been a leading investigator in trials of thrombolytic agents, glycoprotein 2b3a inhibitor agents, thienopyridines, factor Xa inhibitors, lipid lowering agents and new devices. Gibson was named one of the world's most widely published and cited scientists of past decade in 2014 by Thomson Reuters.

Learn more about Dr. Gibson

Clinical Advisory Team

Dr. Mills
Director of Precision Oncology, OHSU Knight Cancer Institute

Dr. Gordon B. Mills earned his M.D. and Ph.D. in biochemistry and completed his training in Obstetrics and Gynecology at the University of Alberta. Prior to moving the Knight Cancer Institute, Dr. Mills was at the MD Anderson Cancer Center, the number one ranked Cancer Center in the United States. He fulfilled multiple roles including founding chair of the Department of Systems Biology, co-Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy co-Director of the Kleberg Center for Molecular Markers and holds the Olga Keith Wiess Distinguished University Chair for Cancer Research at the MD Anderson Cancer Center. At the Knight Cancer Institute at the Oregon Health Sciences University, Dr. Mills is Director of Precision Oncology and SMMART trials.

Learn more about Dr. Mills
Dr. Deane
Endowed Chair for Rheumatology Research, University of Colorado Denver

A variety of autoimmune diseases have a ‘preclinical’ period of development where blood or other tests can show abnormalities in the immune system sometimes years prior to someone feeling ‘sick’. Dr. Deane’s research is focused primarily on the preclinical rheumatoid arthritis (RA). Dr. Deane is currently a principal or co-investigator in several multi-centered studies investigating how genetics and environmental factors influence the early development of RA. He also has special interests in the role of the lung and other mucosal sites in the development of RA.​ Dr. Deane is also the Principal Investigator on an NIH-sponsored clinical trial for the prevention of RA that is entitled ‘Strategy for the Prevention of RA, or 'StopRA'.

Learn more about Dr. Deane
Dr. Niewold
Director of the NYU Colton Center for Autoimmunity

Dr. Niewold is the Judith and Stewart Colton Professor of Medicine, Department of Medicine, and Professor, Department of Pathology at New York University Grossman School of Medicine. He also serves as the Director of the Colton Center for Autoimmunity.Dr. Niewold is a physician-scientist working as a human geneticist and translational researcher. His lab focuses on identifying and understanding the causes of autoimmune disease and how genetic risk factors impact the immune response. His work has contributed to the underlying genetic basis of lupus and the role of type I interferon in triggering the disease.Dr. Niewold is the 2015 recipient of the Mary Betty Stevens Young Investigator Prize. He serves on the Grants Review Subcommittee of the Foundation's Medical-Scientific Advisory Council.

Learn more about Dr. Niewold
Dr. Tsimikas
Director of Vascular Medicine at UC-San Diego Health

Dr. Tsimikas is Professor of Medicine and Director of Vascular Medicine at the University of California San Diego. He is trained in internal medicine, general and interventional cardiology and vascular medicine. He oversees a translational cardiovascular research laboratory focused on “biotheranostics” - biomarkers, therapeutics and molecular imaging. He has a dual appointment as UCSD and as Cardiovascular Franchise Leader and Vice President of Clinical Development at Ionis Pharmaceuticals. Dr. Tsimikas has published over 300 articles and book chapters, including in NEJM, Lancet, Cell, Nature, JACC, EHJ, Circulation, Circ Res, ATVB, and JLR. He is Fellow of the American College of Cardiology, the American Heart Association and the Society for Cardiac Angiography and Interventions.

Learn more about Dr. Tsimikas
Dr. Davidson
Director of Preventive Cardiology at University of Chicago Medicine

Dr. Michael H. Davidson is Director of the Lipid Clinic at the University of Chicago, Pritzker School of Medicine. He also serves as Chief Medical Officer and Executive Vice President for Omthera Pharmaceuticals. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine in Columbus. He then completed his residency and fellowship in cardiology at Rush University Medical Center in Chicago.

Learn more about Dr. Davidson